Pasithea Therapeutics (KTTA) Cash from Operations (2021 - 2026)
Pasithea Therapeutics (KTTA) posted Cash from Operations of 4787220.0 for Q1 2026, up 11.3% sequentially from 5396822.0 in Q4 2025, and down 56.66% YoY from 11046324.32 in Q1 2025.
Pasithea Therapeutics (KTTA) Cash from Operations (2021 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Cash from Operations for 6 years, with the latest figure at 4787220.0 in Q1 2026.
- Quarterly Cash from Operations fell 56.66% year-over-year to 4787220.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16942953.0 (down 33.85% YoY) and the FY2025 annual result came in at 15211490.0, down 9.25% from the prior year.
- Cash from Operations improved to 4787220.0 in Q1 2026 per KTTA's latest filing, from 5396822.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1935427.0 in Q2 2022 and troughed at 5396822.0 in Q4 2025.
- A 5-year average of 3448873.41 and a median of 3202278.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations plunged 742.68% in 2022, then gained 29.94% in 2023.
- Over 5 years, Cash from Operations stood at 3185388.0 in 2022, then declined by 3.42% to 3294344.0 in 2023, then rose by 25.84% to 2443036.0 in 2024, then sank by 120.91% to 5396822.0 in 2025, then increased by 11.3% to 4787220.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 4787220.0, 5396822.0, and 2890025.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | -4.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.79 Mn |
| Mar 31, 2026 | -4.79 Mn |
| Dec 31, 2025 | -5.40 Mn |
| Dec 31, 2025 | -5.40 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Jun 30, 2025 | -3.87 Mn |
| Jun 30, 2025 | -3.87 Mn |
| Mar 31, 2025 | -3.06 Mn |
| Mar 31, 2025 | -3.06 Mn |
| Dec 31, 2024 | -2.44 Mn |
| Dec 31, 2024 | -2.44 Mn |
| Sep 30, 2024 | -3.12 Mn |
| Sep 30, 2024 | -3.12 Mn |
| Jun 30, 2024 | -4.04 Mn |
| Jun 30, 2024 | -4.04 Mn |
| Mar 31, 2024 | -4.32 Mn |
| Mar 31, 2024 | -4.32 Mn |
| Dec 31, 2023 | -3.29 Mn |
| Dec 31, 2023 | -3.29 Mn |